{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-24-000019","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.431766+00:00","generated_at":"2026-06-02T21:55:07.095304+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere Q1: FILSPARI sales $19.8M; FDA Priority Review for full approval by Sept 5","bullets":["Net product sales $40.0M (Q1 2024), up from $24.2M YoY, driven by FILSPARI launch.","FILSPARI net sales $19.8M; 511 new PSFs in Q1, total 1,963 since launch.","FDA granted Priority Review for sNDA to convert accelerated approval to full approval for IgAN; PDUFA Sept 5, 2024.","Net loss $136.1M ($1.76/share) vs $86.3M loss in Q1 2023, including $65M IPR&D milestone for pegtibatinase.","Cash, equivalents, and securities $441.0M as of March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-24-000019","json":"https://secwatch.observer/filing/0001438533-24-000019.json","markdown":"https://secwatch.observer/filing/0001438533-24-000019.md","text":"https://secwatch.observer/filing/0001438533-24-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/0001438533-24-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/tvtx-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:55:07.095304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bfdc2ca28e96e76c06b572ac59abbe647d0aec14","claim":"Travere Therapeutics, Inc. reported the first quarter of 2024 results: revenue $40.0 million, net income $136.1 million, or $1.76 per basic share, EPS $1.76 per basic share.","evidence_excerpt":"Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/0001438533-24-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"$40.0 million"},{"label":"Net income","value":"$136.1 million, or $1.76 per basic share"},{"label":"EPS","value":"$1.76 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}